DV Research Insights

Welcome to our Research Highlights section, where we showcase the cutting-edge work done by our lab and collaborators. Dive into our recent discoveries and see how we’re pushing the boundaries in the field of breast cancer research.

Explore Our Publications on PubMed: For a comprehensive list of all our lab publications, visit our PubMed profile.

Featured Publications:

2023

• Luminal Breast Cancer Identity: Our study “Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity” by Prekovic S. et al., published in EMBO Mol Med, explores the critical role of glucocorticoid receptor activity in defining luminal breast cancer identity. Read more.
• Epi-Transcriptomic Landscape in ER+ Breast Cancer: In “Dynamic epi-transcriptomic landscape mapping with disease progression in estrogen receptor-positive breast cancer” by Keelan S. et al., published in Cancer Commun, we delve into the changes in RNA methylation and their impact on disease progression. Read more.

2022

• Immune Microenvironment in Brain Metastasis: “Characterisation of the immune microenvironment of primary breast cancer and brain metastasis reveals depleted T-cell response associated to ARG2 expression” by Giannoudis A. et al., in ESMO Open, sheds light on the immune landscape in breast cancer and brain metastasis. Read more.
• Radiosensitive Brain Metastases: The study “Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism” by Monteiro C. et al., published in Nat Med, discusses new insights into treating radiosensitive brain metastases. Read more.
• Dexamethasone and Breast Cancer Stem Cells: In “Dexamethasone promotes breast cancer stem cells in obese and not lean mice” by Annett S. et al., in Pharmacol Res Perspect, we explore the interaction between obesity, medication, and cancer stem cells. Read more.
• Drug-Screening for Brain Metastasis: “A clinically compatible drug-screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis” by Zhu L. et al., in EMBO Mol Med, highlights our advancements in screening drugs for brain metastasis treatment. Read more.
• Molecular Subtype Specific Alterations in Brain Metastases: Our work “Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities” by Cosgrove N. et al., in Nat Commun, focuses on identifying vulnerabilities in breast cancer brain metastases. Read more.
• 2021
• AIB1 Interactome in Breast Cancer: “Comparative analysis of the AIB1 interactome in breast cancer reveals MTA2 as a repressive partner which silences E-Cadherin to promote EMT and associates with a pro-metastatic phenotype” by Varešlija D. et al., published in Oncogene, dives into the AIB1 protein’s interactions and their role in breast cancer’s aggressive behavior. Read more.
• 2020
• Targeting Breast Cancer Brain Metastasis: In “ADAM22/LGI1 complex as a new actionable target for breast cancer brain metastasis” by Charmsaz S. et al., featured in BMC Med, our team identifies a novel target for treating brain metastasis in breast cancer. Read more.
• Brain Metastasis Cell Lines Panel: “Brain Metastasis Cell Lines Panel: A Public Resource of Organotropic Cell Lines” by Valiente M. et al., in Cancer Res, provides a valuable resource for studying brain metastasis, showcasing our commitment to collaborative research. Read more.
• FiTAc-seq for FFPE Tissues: Our study “FiTAc-seq: fixed-tissue ChIP-seq for H3K27ac profiling and super-enhancer analysis of FFPE tissues” by Font-Tello A. et al., in Nat Protoc, introduces a new method for analyzing fixed tissues, broadening the scope of epigenetic research. Read more.
• 6-Hydroxydopamine Review: “6-Hydroxydopamine: a far from simple neurotoxin” by Varešlija D. et al., in J Neural Transm, offers a comprehensive review of this neurotoxin, contributing to a deeper understanding of its effects. Read more.
  • 2019
• MicroRNAs in Brain Metastasis: “A novel panel of differentially-expressed microRNAs in breast cancer brain metastasis may predict patient survival” by Giannoudis A. et al., in Sci Rep, reveals the potential role of microRNAs in predicting outcomes for breast cancer brain metastasis. Read more.
• Therapeutic Strategy for Lobular Breast Cancer: In “BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer” by Walsh L. et al., in Clin Cancer Res, we explore new therapeutic avenues for a specific subtype of breast cancer. Read more.
• AI-Resistant Breast Cancer Research: “Altered Steroid Milieu in AI-Resistant Breast Cancer Facilitates AR Mediated Gene-Expression Associated with Poor Response to Therapy” by Creevey L. et al., in Mol Cancer Ther, investigates the challenges of hormone therapy resistance in breast cancer. Read more.
• 2018
• Breast Cancer Prognostic Indicator: “Low cleaved caspase-7 levels indicate unfavourable outcome across all breast cancers” by Lindner AU. et al., in J Mol Med, provides insights into a potential prognostic indicator for breast cancer. Read more.
• Breast and Brain Metastatic Tumors: “Transcriptome Characterization of Matched Primary Breast and Brain Metastatic Tumors to Detect Novel Actionable Targets” by Varešlija D. et al., in J Natl Cancer Inst, explores genetic differences in primary and metastatic tumors. Read more.
• Advanced Breast Cancer Research: “Epigenome-wide SRC-1-Mediated Gene Silencing Represses Cellular Differentiation in Advanced Breast Cancer” by Ward E. et al., in Clin Cancer Res, discusses the role of gene silencing in breast cancer progression. Read more.
• Network Analysis in Breast Cancer: “Network analysis of SRC-1 reveals a novel transcription factor hub which regulates endocrine resistant breast cancer” by Browne AL. et al., in Oncogene, sheds light on the complex network of genes involved in breast cancer resistance. Read more.
• Pre 2018
• Breast Cancer Brain Metastases Study: “Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases” by Priedigkeit N. et al., in JAMA Oncol, examines the genetic changes in brain metastases from breast cancer. Read more.
• Breast Cancer Xenografts: “Patient-Derived Xenografts of Breast Cancer” by Varešlija D. et al., in Methods Mol Biol, highlights the use of xenografts in breast cancer research. Read more.
• AI Therapy in Breast Cancer: “Adaptation to AI Therapy in Breast Cancer Can Induce Dynamic Alterations in ER Activity Resulting in Estrogen-Independent Metastatic Tumors” by Varešlija D. et al., in Clin Cancer Res, investigates the adaptations of breast cancer cells to hormone therapy. Read more.
• Metastatic Expression Changes in Breast Cancer: “Transcriptomic Profiling of Sequential Tumors from Breast Cancer Patients Provides a Global View of Metastatic Expression Changes Following Endocrine Therapy” by McBryan J. et al., in Clin Cancer Res, offers insights into the genetic changes in breast cancer following endocrine therapy. Read more.
• AIB1 in Aromatase Inhibitor-Resistant Breast Cancer: “AIB1:ERα transcriptional activity is selectively enhanced in aromatase inhibitor-resistant breast cancer cells” by O’Hara J. et al., in Clin Cancer Res, discusses the role of AIB1 in resistance to breast cancer treatment. Read more.